Key result
The MiStent SES demonstrated a two-year MACE rate of 6.7% compared to 13.3% for the Endeavor stent (p=0.167), with no probable or definite stent thrombosis reported up to two years.
Why the study?
Does the MiStent SES reduce MACE compared to the Endeavor stent in patients undergoing coronary stenting?
RCT (n=209)
Does the MiStent SES reduce MACE compared to the Endeavor stent in patients undergoing coronary stenting?
Absolute Event Rate: 6.7% vs 13.3%
p-value: p=0.167
The MiStent SES demonstrated good long-term safety and effectiveness with low two-year MACE rates, comparable to the Endeavor stent.
Comparable two-year MACE rates support MiStent as an alternative; extends RCT evidence of durable outcomes versus Endeavor.
AIMS: Our aim was to evaluate the two-year clinical results of a new sirolimus-eluting stent (MiStent SES) with a bioabsorbable coating designed for rapid polymer dissolution but sustained drug delivery. METHODS AND RESULTS: Major adverse cardiac events (MACE), target lesion failure (TLF), target vessel failure (TVF), and stent thrombosis (ST) at two-year follow-up are reported for the DESSOLVE I and II trials. In DESSOLVE I, the MiStent SES (n=29) demonstrated a 3.4% two-year MACE rate without TLF or TVF. In DESSOLVE II, the MiStent group had a 6.7% (8/120) two-year MACE rate compared to 13.3% (8/60) for Endeavor (p=0.167). TLF was 5.0% in the MiStent and Endeavor groups (p=1.00). TVF was 5.0% for MiStent versus 11.7% for Endeavor (p=0.129). No probable or definite ST was reported with the MiStent up to two years. The median duration of dual antiplatelet therapy (DAPT) in DESSOLVE I and II was 364 and 366 days, respectively. CONCLUSIONS: The MiStent SES demonstrated good long-term safety and effectiveness with low two-year MACE, TLF, and TVF rates.
No takes yet. Share an insight, caveat, or question.
Wijns et al. (2016) conducted an RCT in Coronary artery disease (n=209). MiStent SES (crystalline sirolimus-eluting coronary stent) vs. Endeavor stent was evaluated on Major adverse cardiac events (MACE) (p=0.167). The MiStent SES demonstrated a two-year MACE rate of 6.7% compared to 13.3% for the Endeavor stent (p=0.167), with no probable or definite stent thrombosis reported up to two years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: